SMS Pharmaceuticals Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/w4wupc16vomw5pcs0di4cbzg.pdf

Key Takeaways


Ibuprofen: The Volume-Margin Transition

Vamsi Krishna Potluri: "I think we will be hitting the 600 ton mark maybe in a year or so from now. I think less than a year, I think we should probably be hitting in maybe in two or three quarters. I think we should be hitting the 600 ton, 650 ton range actually."

Segment Performance

SegmentTrendCommentary
ARV▲ Strong resurgenceTendering activity gained momentum after COVID-era delays; tenders now completed, with stable orders expected going forward. Margins are limited on CMO products sold as commodities.
Ibuprofen▲ RampingFavourable month-on-month growth; market landscape expected to transform in upcoming quarters. Company demonstrated ability to leverage existing market gaps.
Sitagliptin▲ HealthyPositive momentum expected to sustain; company holds 40% market share in Europe.
Anti-ulcer▲ StrongOne of the company's most robust segments since inception; growth remains strong and expected to maintain momentum.
Anti-diabetic▼ Revenue declinePrice erosion is the primary factor, not volume decline; volumes grew consistently. High base effect from exceptional Q2 FY23 also contributed. Company reduced prices to help partners retain market share and is implementing backward integration to protect profitability.

Cost Structure & Margin Dynamics


Strategic Direction & Pipeline

Vamsi Krishna Potluri: "At this point of time, we are majorly focused on the generic space -- the generic drugs. But definitely, I think down the line, that is the thought process... we are definitely looking at some niche categories and niche segment CDMO opportunities as well. So, we are in discussions with a couple of customers, but nothing is finalized yet."

Guidance & Commitments

CommitmentSpecificsTimeline
Ibuprofen volume rampReach 600–650 tons per month2–3 quarters
Capacity utilizationCross 75% utilization rateBy end of FY25
Revenue target₹1,000 croresBy FY28
Annual growth rate~15% year-on-yearOngoing (next 2–3 financial years)
H2 margin maintenanceGross and EBITDA margins at H1 levels, barring geopolitical escalationH2 FY24
Capex postureNo major expansion; small regular capex onlyUntil 75% utilization achieved

Key Metrics

MetricQ2 FY24
Revenue₹167 cr, +5% YoY
Operating profit₹28 cr, +105% YoY
Net profit₹12 cr, recovered from a loss in Q2 FY23
API segment revenue₹162.9 cr, 97.8% of consolidated revenue
API export share87% of API revenue, including deemed exports
Gross margin outlookSimilar to H1 FY24 for the full year, barring geopolitical escalation
EBITDA margin outlookSimilar to H1 FY24 for the full year, barring geopolitical escalation
Revenue growth guidance~15% year-on-year
Revenue target₹1,000 cr by FY28
Overall capacity utilization50% to 60%, expected to cross 75% by end of FY25
Ibuprofen installed capacity750 metric tons per month
Ibuprofen production250 to 300 metric tons per month, utilization of ~40% to 44%
Ibuprofen target production600 to 650 metric tons per month, expected in 2 to 3 quarters
Ibuprofen realization~₹700 per kg, stable within ₹10 to ₹20
Sitagliptin European market share40%